Compare Firy Inc. (FIRY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Sanofi SA — how do they compare? Firy Inc. trades at $8.39 (market cap $125.48M), while Sanofi SA trades at $44.14 (market cap $103.94B). The key difference: Sanofi SA is far larger — about 828.3× Firy Inc.'s market cap, and Sanofi SA pays a 5.54% dividend while Firy Inc. pays none. Which is the better fit depends on your goals.
| FIRY | SNY | |
|---|---|---|
Market Cap | $125.48M | $103.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $52.34 |
52-Week Low | $2.28 | $41.33 |
Enterprise Value | $69.16M | $120.43B |
Dividend Yield | — | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $8.39, up 4.35% today, with a bullish technical signal from moving averages and RSI near oversold levels. The company recently rebranded from Skillz Inc. and reported Q1 2026 revenue growth but continues significant losses, with a net income margin of -57.48%. Cash flow remains negative, though operating losses have narrowed from prior years.
Outlook is mixed: technical momentum and revenue stabilization offer potential upside, but persistent losses, negative cash flow, and weak profitability metrics pose substantial risks. Analyst consensus is neutral with 60% hold ratings, reflecting cautious optimism amid ongoing financial challenges.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
